Yale Cancer Center NCTN LAPS

项目摘要 在查尔斯博士的领导下，耶鲁癌症中心继续参与NCTN Fuchs不仅包括NCTN试验强大和坚定的收益历史，而且 在SWOG和其他组织的试验工作中发挥强有力的领导作用。YCC将继续致力于 在所有YCC临床中心优先进行NCTN试验，并展示超过年度收益 在我们目前的U10奖项中制定的估计。就目前提交的文件而言， YCC领导层将：1)继续优先考虑NCTN试验，并将YCC发展为 团体试验的主要贡献者，以及我们护理中心的额外贡献；2)促进和 通过以下方式鼓励YCC教职员工在SWOG和其他NCTN小组中发挥领导作用 支持他们的时间和努力并奖励这些活动；以及3)利用我们的NCTN 协调委员会(NCC)作为将耶鲁翻译科学带入集团的桥梁 作为我们的研究人员发起的试点试验的结果，活动对于多中心来说是有希望的 和随机问题。除了福克斯博士的领导努力外，SWOG的其他关键人物 领导者包括罗伊·赫布斯特博士、丹尼尔·佩特里拉克博士和拉霍斯·普兹泰博士。罗伊·彼得·格雷泽博士 除了芭芭拉博士，德克尔和亚历山德罗·桑丁还将领导我们在NRG小组的工作 他将继续领导我们在ECOG-ACRIN小组的努力。我们相信， YCC的科学和翻译工作有很大潜力被纳入NCTN 程序。继续研究早期药物开发、EGFR耐药性、PD-1信号转导、 化学生物学和YCC科学计划在信号转导方面的新靶点 有很强的转化为集体试验的潜力。此外，随着Smilow的扩张 癌症医院护理中心，我们展示了将NCTN试验引入到 康涅狄格州更多的病人。这笔UG1赠款将帮助我们 发展适当的领导层和基础设施，以支持NCTN小组的主要工作 在应计和计划开发方面。

Project Summary Yale Cancer Center's continuing participation in the NCTN under the leadership of Dr. Charles Fuchs includes not only a solid history of strong and committed accrual to NCTN trials, but strong leadership in the trials efforts at SWOG and other groups. YCC remains committed to prioritizing NCTN trials at all the YCC clinical centers and demonstrates annual accrual beyond estimates developed in our current U10 award. For this current submission, the vision of the YCC leadership is to: 1) continue to prioritize NCTN trials for accrual and develop YCC as a major contributor to group trials with additional contribution of our Care Centers; 2) facilitate and encourage YCC faculty to assume leadership roles in SWOG and other NCTN groups by supporting their time and effort and rewarding these activities; and 3) leverage our NCTN Coordinating Committee (NCC) as a bridge to bring Yale translational science to group activities as the results of our investigator initiated pilot trials become promising for multi-center and randomized questions. In addition to the leadership efforts of Dr. Fuchs, other key SWOG leaders include Drs. Roy Herbst, Daniel Petrylak and Lajos Pusztai. Drs. Peter Glazer, Roy Decker and Alessandro Santin will lead our efforts in the NRG group in addition to Dr. Barbara Burtness who will continue to lead our efforts in the ECOG-ACRIN group. We believe that the science and translational work at YCC has strong potential for incorporation into NCTN programs. Continued work on early phase drug development, EGFR resistance, PD-1 signaling, chemical biology, and new targets in signal transduction through the scientific programs of YCC have strong potential for translation into group trials. Furthermore, with expansion of the Smilow Cancer Hospital Care Centers, we demonstrated a greater opportunity to bring NCTN trials to the greater patient population across the state of Connecticut. This UG1 grant will assist us in developing the appropriate leadership and infrastructure for support of key NCTN group efforts in both accrual and program development.